Literature DB >> 12451379

IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature.

Robert M Vodegel1, Marcelus C J M de Jong, Hendri H Pas, Marcel F Jonkman.   

Abstract

We describe 2 adult patients with a subepidermal bullous dermatosis with exclusively linear IgA depositions along the epidermal basement membrane zone that were deposited in the sublamina densa zone as witnessed by direct immunoelectron microscopy. Indirect immunofluorescence microscopy of patients' sera revealed circulating IgA autoantibodies that bound exclusively to the dermal site of salt-split skin substrate. Immunoblot analysis using dermal and keratinocyte extracts were negative. Indirect immunofluorescence microscopy using type VII collagen-deficient skin ("knockout" substrate) showed no IgA binding, whereas linear IgA binding was seen at the epidermal basement membrane zone in normal human skin. The autoantigen in the patients was thus type VII collagen. A diagnosis of IgA-mediated epidermolysis bullosa acquisita (IgA-EBA) was made. We systematically reviewed the literature of this subset of patients with linear IgA dermatosis on the basis of the following criteria: exclusive binding of serum-IgA to the dermal side of salt-split skin or IgA depositions in the sublamina densa zone by indirect or direct immunoelectron microscopy. We learned that IgA-EBA is clinically indistinguishable from the classic "lamina-lucida type" linear IgA dermatosis or from the inflammatory type of IgG-mediated epidermolysis bullosa acquisita (IgG-EBA). Only a minority of the patients with IgA-EBA showed milia or scarring or had therapy-resistant ocular symptoms as in the mechanobullous type of IgG-EBA. Most patients with IgA-EBA responded to dapsone therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451379     DOI: 10.1067/mjd.2002.125079

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

Review 1.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Autoimmunity to type VII collagen in SKH1 mice is independent of regulatory T cells.

Authors:  L Chen; J D Peterson; W-Y Zheng; S-X Lin; L S Chan
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

3.  ["Decoratively figured blisters" on the whole integument in initially diagnosed ulcerative colitis].

Authors:  Wolfgang Konschake; Georg Daeschlein; Michael Jünger; Stine Lutze
Journal:  Hautarzt       Date:  2019-03       Impact factor: 0.751

4.  Epidermolysis bullosa acquisita.

Authors:  Denise Miyamoto; Juliana Olivieri Gordilho; Claudia Giuli Santi; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2022-06-11       Impact factor: 2.113

5.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

6.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

Review 7.  Epidermolysis bullosa acquisita: current diagnosis and therapy.

Authors:  Christine R Mehren; Robert Gniadecki
Journal:  Dermatol Reports       Date:  2011-11-28

8.  Linear IgA bullous dermatosis: a rare side effect of vancomycin.

Authors:  Pradeep K Selvaraj; Faisal A Khasawneh
Journal:  Ann Saudi Med       Date:  2012-07-01       Impact factor: 1.526

Review 9.  Molecular diagnosis in autoimmune skin blistering conditions.

Authors:  J V Otten; T Hashimoto; M Hertl; A S Payne; C Sitaru
Journal:  Curr Mol Med       Date:  2014-01       Impact factor: 2.222

Review 10.  Immunopathology and molecular diagnosis of autoimmune bullous diseases.

Authors:  Sidonia Mihai; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2007 May-Jun       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.